Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) Interest & Investment Income (2021 - 2026)

Barinthus Biotherapeutics (BRNS) has disclosed Interest & Investment Income for 6 consecutive years, with $350000.0 as the latest value for Q1 2026.

  • For Q1 2026, Interest & Investment Income fell 37.05% year-over-year to $350000.0; the TTM value through Mar 2026 reached $1.8 million, down 28.79%, while the annual FY2025 figure was $2.0 million, 26.92% down from the prior year.
  • Interest & Investment Income hit $350000.0 in Q1 2026 for Barinthus Biotherapeutics, down from $406000.0 in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $1.6 million in Q1 2023 and bottomed at $83000.0 in Q1 2022.
  • Average Interest & Investment Income over 5 years is $645000.0, with a median of $571000.0 recorded in 2023.
  • Year-over-year, Interest & Investment Income skyrocketed 4050.0% in 2022 and then plummeted 80.86% in 2023.
  • Barinthus Biotherapeutics' Interest & Investment Income stood at $1.3 million in 2022, then tumbled by 56.97% to $571000.0 in 2023, then grew by 11.56% to $637000.0 in 2024, then crashed by 36.26% to $406000.0 in 2025, then fell by 13.79% to $350000.0 in 2026.
  • According to Business Quant data, Interest & Investment Income over the past three periods came in at $350000.0, $406000.0, and $472000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.